AstraZeneca is building its first biologics manufacturing campus in Singapore—an USD 1.5billion investment that will serve as a global hub for innovation and excellence. This state‑of‑the‑art facility will deliver end‑to‑end Antibody‑Drug Conjugate (ADC) capabilities under one roof:

• Small molecule chemical API production
• Large molecule antibody manufacturing
• Conjugation
• Fill‑and‑finish operations, including sterile filling and lyophilization

The site will be equipped with cutting‑edge digital and automation infrastructure, enabling autonomous manufacturing powered by artificial intelligence. It will be designed for carbon neutrality, embedding sustainability into every aspect of operations and setting a new benchmark for environmentally responsible biologics manufacturing.

We are looking for passionate individuals with relevant experience who thrive in dynamic environments and ...